Hyunsoo Ha

Hyunsoo Ha

Auto-generated profile, based on publicly available information

Hyunsoo Ha

College of Pharmacy, Korea University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2021 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
HHHyunsoo Ha
Hyunsoo Ha
HKHongmok Kwon
Hongmok Kwon
TLTaehyeong Lim
Taehyeong Lim
JJJaebong Jang
Jaebong Jang
SPSong-Kyu Park
Song-Kyu Park
YBYoungjoo Byun
Youngjoo Byun
Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II, is a potential target protein for the imaging and treatment of patients with prostate cancer because of its o...

11 December 2021 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
SLSeulgi Lee
Seulgi Lee
BPBernie Byeonghoon Park
Bernie Byeonghoon Park
HKHongmok Kwon
Hongmok Kwon
VKVitchan Kim
Vitchan Kim
JJJang Su Jeon
Jang Su Jeon
YBYoungjoo Byun
Youngjoo Byun
Inositol hexakisphosphate kinase (IP6K) is an important mammalian enzyme involved in various biological processes such as insulin signalling and blood clotting. Recent analyses on drug metabolism and pharmacokinetic properties on TNP (N2-(m-trifluorobenzyl), N6-(p-nitrobenzyl)purine), a pan-IP6K inhibitor, have suggested that it may inhibit cytochrome P450 (CYP450) enzymes and induce unwanted drug-drug interactions in the liver. In this study, we confirmed that TNP inhibits CYP3A4 in type I binding mode more selectively than the other CYP450 isoforms. In an effort to find novel purine-based IP6K inhibitors with minimal CYP3A4 inhibition, we designed and synthesised 15 TNP analogs. Structure-activity relationship and biochemical studies, including ADP-Glo kinase assay and quantification of cell-based IP7 production, showed that compound 9 dramatically reduced CYP3A4 inhibition while retaining IP6K-inhibitory activity. Compound 9 can be a tool molecule for structural optimisation of purine-based IP6K inhibitors.